Cagrilintide
Reduces appetite for sustained weight loss
- Appetite Suppression
- Weight Loss
Thyroid C-cell tumor risk observed in rodent studies — human relevance uncertain but precaution advised; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome Monitor for signs of pancreatitis (severe abdominal pain) — discontinue if suspected Gastroparesis risk especially when combined with GLP-1 agonists — monitor for severe or persistent GI symptoms Significant weight loss may include muscle mass — resistance training strongly recommended to preserve lean body mass
Mechanism of Action
Cagrilintide is a long-acting, lipidated amylin analogue that acts as a dual agonist at both amylin receptors and calcitonin receptors in the brain. By binding to these receptors, particularly in areas like the area postrema and hypothalamus, it enhances satiety signaling and reduces food intake through mechanisms that complement but are distinct from GLP-1 receptor activation. Key Pathways: Amylin receptor (AMY1, AMY2, AMY3) activation in central nervous system satiety centers, Calcitonin receptor (CTR) signaling contributing to appetite suppression, Area postrema and hypothalamic energy homeostasis regulation By activating amylin and calcitonin receptors in brain regions controlling appetite, cagrilintide produces dose-dependent reductions in body weight through decreased food intake and enhanced feelings of fullness. When combined with semaglutide (a GLP-1 receptor agonist), the two compounds target complementary pathways, potentially producing greater weight loss than either agent alone.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Cagrilintide protocols — frequency, timing, cycle length, reconstitution & research
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Gastroparesis risk
- Injection site reactions
- Pancreatitis warning
- Thyroid C-cell tumor risk